Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
JENTADUETO vs SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and decreasing glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
Oral, 50 mg sitagliptin/500 mg metformin twice daily or 50 mg sitagliptin/1000 mg metformin twice daily, individually titrated based on glycemic response and tolerability. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.
None Documented
None Documented
Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Sitagliptin: 12.4 h; metformin: 6.2 h (prolonged in renal impairment).
Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Renal: sitagliptin ~87% unchanged in urine; metformin ~90% unchanged in urine. Biliary/fecal: minimal.
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor